Product Description
Addressing the growing threat of drug resistance and demand for extended protection windows (3-6 months), our deworming solutions focus on novel chemical entity (NCE) screening against next-generation targets (e.g., post-isoxazoline classes), long-acting delivery systems (including 6-month sustained-release transdermal formulations and subcutaneous implants), and multi-indication combination products for comprehensive parasite and heartworm prevention. Leveraging core APIs, sustained-release technologies, and drug-loaded chip systems, we redefine convenience and efficacy in pet parasitic disease control.
